[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Institute of Hypertension\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100576098","protecting-renal-function-in-chronic-kidney-disease-patients-with-isolated-nighttime-hypertension-100576098",false,"NCT06780865","Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension","Protection of Renal Function by Antihypertensive Treatment in Patients with Chronic Kidney Disease and Isolated Nighttime Hypertension","PRECISE","Inclusion Criteria:\n\n* Participants must be 18 years of age or older. All genders are eligible;\n* Confirmed diagnosis of Chronic Kidney Disease (CKD) according to KDIGO. guidelines;\n* UACR \\\u003C 30 mg\u002Fg (3.4 mg\u002Fmmol) and eGFR between 20-44 mL\u002Fmin\u002F1.73 m²; or UACR between 30-300 mg\u002Fg (3.4-33.9 mg\u002Fmmol) and eGFR between 20-59 mL\u002Fmin\u002F1.73 m²; or UACR between 300-5000 mg\u002Fg (33.9-565 mg\u002Fmmol) and eGFR \\> 20 mL\u002Fmin\u002F1.73 m² (CKD-EPI equation).\n* Office blood pressure measurements below 140\u002F90 mmHg at both screening visits;\n* Daytime ambulatory blood pressure \\\u003C 135\u002F85 mmHg and nighttime systolic blood pressure ≥ 120 mmHg or diastolic blood pressure ≥ 70 mmHg;\n* No use of corticosteroids, immunosuppressants, or biologic agents for at least one month prior to enrollment;\n\nExclusion Criteria:\n\n* Presence of acute kidney injury or acute renal failure;\n* History of kidney transplantation;\n* Presence of severe arrhythmias, including severe atrial fibrillation, atrioventricular (AV) block, sinoatrial (SA) block, sinus bradycardia, malignant AV node reentrant tachycardia syndrome;\n* Secondary hypertension related to suspected or confirmed renal artery stenosis or adrenal gland disorders;\n* Poor glycemic control (HbA1c \\> 12%);\n* Orthostatic hypotension (a decrease in blood pressure of \\>20\u002F10 mmHg within 3 minutes of standing from a sitting position);\n* Women who are pregnant or breastfeeding at the time of enrollment, or not employing contraception of reproductive age;\n* NYHA (New York Heart Association) Class III-IV congestive heart failure at the time of enrollment;\n* History of myocardial infarction, unstable angina, acute heart failure, stroke, transient ischemic attack (TIA), or cerebral hemorrhage within the 12 weeks prior to enrollment;\n* Underwent coronary revascularization (Percutaneous Coronary Intervention \\[PCI\\] or Coronary Artery Bypass Grafting \\[CABG\\]), or valve repair\u002Freplacement within the 12 weeks prior to enrollment, or planned to undergo any of the aforementioned surgical procedures after randomization;\n* Any other serious diseases outside the renal and cardiovascular domains, including but not limited to malignancies, with an expected survival of less than 2 years based on the investigator's clinical judgment;\n* Presence of active malignancy requiring pharmacological treatment;\n* AST (Aspartate Aminotransferase) or ALT (Alanine Aminotransferase) levels \\>3 times the upper limit of normal (ULN);\n* Total bilirubin \\>2 times ULN. Patients with Gilbert's syndrome who exhibit isolated bilirubin elevation do not need to be excluded;","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","Hypertension guidelines recommend the application of ambulatory blood pressure monitoring in the diagnosis and treatment of patients with hypertension. Subtypes of hypertension such as nocturnal hypertension can be found through ambulatory blood pressure monitoring. Previous studies have reported that the prevalence of nocturnal hypertension, even isolated nocturnal hypertension, is higher in patients with chronic kidney disease, and it is associated with adverse events such as cardiovascular events and progression of renal dysfunction. However, the benefit of controlling nocturnal hypertension in patients with chronic kidney disease is unclear. In this study, a total of 200 patients with chronic kidney disease and isolated nocturnal hypertension will be enrolled. Patients will be randomly divided into two treatment groups: the active antihypertensive treatment group and the placebo treatment group (1:1). The antihypertensive treatment group will be treated with arotinolol or amlodipine and clonidine to control nocturnal blood pressure, while the control group will be treated with the corresponding placebos. Randomized patients will be followed up for 2 years to evaluate the effect of controlling isolated nocturnal hypertension on the progression of chronic kidney disease in terms of EPI-estimated glomerular filtration rate (eGFR) decline and change in proteinuria.",[27,28],"Chronic Kidney Disease(CKD)","Nocturnal Hypertension",[30,31],"chronic kidney disease","isolated nocturnal hypertension","NOT_YET_RECRUITING","2025-01-15",{"date":35,"type":36},"2025-01-17","ACTUAL",{"date":38,"type":21},"2025-01-30",{"date":40,"type":21},"2028-12-31",{"name":42,"class":43},"Shanghai Institute of Hypertension","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100373063","registry-study-on-control-nocturnal-hypertension-to-reach-the-target--100373063","NCT04137549","Registry Study on \"Control Nocturnal Hypertension to Reach the Target \"","Registry Study on \"Control Nocturnal Hypertension to Reach the Target \"（CONTROL-NHT）","CONTROL-NHT","Inclusion Criteria:\n\n* Age 50-79 years old\n* Clinical diagnosed hypertension with the use of antihypertensive drugs\n* Nocturnal hypertension ( nocturnal systolic blood pressure ≥ 130 mmHg and\u002For nocturnal diastolic blood pressure ≥ 80 mmHg)\n* A 24-hour ambulatory blood pressure monitoring was performed with validated equipment.\n* Willing to provide information about disease history and blood biochemical test data within 6 months.\n* Sign the informed consent\n\nExclusion Criteria:\n\n* Without antihypertensive drug use\n* Hospitalized hypertension patients\n* Non-compliant patient","50 Years","79 Years",{"count":55,"type":21},4500,"3 Years","OBSERVATIONAL","Ambulatory blood pressure monitoring (ABPM) is a major innovation in the history of hypertension diagnosis. In clinical practice, the most well established indication for using ABPM is to identify patients who have high BP readings in the office but normal readings during usual daily activities outside of this setting or vice versa, and to identify varying 24-h BP profiles. However, in recent years, there has been increasing interest in BP values during sleep, and nocturnal BP is now recognized to be superior to daytime BP in predicting fatal and nonfatal cardiovascular events (stroke, myocardial infarction, and cardiovascular death), especially in medicated patients.\n\nThe current direction in the management of hypertension is toward earlier and lower BP control for 24 hours, including the nocturnal and morning periods. Therefore, it may be of great significance to pay attention to the management of nocturnal blood pressure so as to reduce the increased cardiovascular risks.\n\nInformation of nocturnal hypertensive patients defined by ABPM was prospectively registered nationwide, and then to investigate whether there was difference in cardiovascular prognosis according to the control of ambulatory nocturnal blood pressure.",[28],[61,62,63],"ambulatory blood pressure monitoring","nocturnal hypertension","cardiovascular risk","RECRUITING","2025-01-03",{"date":67,"type":36},"2025-01-06",{"date":69,"type":36},"2019-12-01",{"date":71,"type":21},"2026-12-31",{"name":42,"class":43},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":73},"100505252","home-blood-pressure-intervention-in-the-community-trial-100505252","NCT05858944","Home Blood Pressure Intervention in the Community Trial","Inclusion Criteria:\n\n* Aged 60-80 years old\n* Have been taking antihypertensive drugs for more than 2 weeks\n* The average SBP and\u002For DBP of 7-day home blood pressure monitoring ≥135\u002F85 mmHg\n* Willing to participate, adhere to follow-up, and sign the written informed consent form\n\nExclusion Criteria:\n\n* Arm circumference too large or too small (less than 18 cm or greater than 42 cm) to fit the cuff in case of inaccurate measurement\n* Invalid home blood pressure monitoring. The valid home blood pressure monitoring requires consecutive measurements for at least 3 days, with not less than 1 measurement in the morning and evening, respectively.\n* Office blood pressure indicates stage 3 clinic hypertension (≥180\u002F110 mmHg) during the screening period\n* Suspected or known secondary hypertension\n* Orthostatic hypotension, defined as a decrease in systolic blood pressure greater than 20 mmHg or diastolic blood pressure greater than 10 mmHg within 3 minutes when position is changed from sitting to standing\n* eGFR\\\u003C30 ml\u002Fmin\u002F1.73m2 or end-stage renal disease\n* Cardiovascular events occured within the past 3 months, such as myocardial infarction, stroke, acute heart failure, hospitalization for unstable angina, undergoing coronary artery revascularization or bypass grafting\n* Abnormal liver function (ALT\u002FAST\u002Ftotal bilirubin more than 2 times the upper limit of normal value)\n* Severe somatic disease with a life expectancy of less than 3 years, or diagnosed with cancer within the past 2 years requiring treatment\n* Doctors deem that the participation would do harm to the patients or the patients would have poor compliance.","60 Years","80 Years",{"count":83,"type":21},10000,[24],"The primary purpose of the study is to explore whether a lower home blood pressure target (125\u002F75 v.s. 135\u002F85 mmHg) would be beneficial to elderly treated hypertensive patients in terms of reduced incidence of cardiovascular events. The study also aims to promote the application of standardised and information-based home blood pressure monitoring in community hypertension management.",[87],"Home Blood Pressure","2025-01-02",{"date":67,"type":36},{"date":91,"type":36},"2023-05-06",{"date":93,"type":21},"2030-06-30",{"name":42,"class":43},""]